<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Kjellstadli C</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To investigate differences in cardiovascular disease (CVD) morbidity and mortality after radical prostatectomy or definitive radiotherapy with or without androgen deprivation therapy (ADT).&lt;h4>Materials and methods&lt;/h4>We used population-based data from the Cancer Registry of Norway, the Norwegian Patient Registry and the Norwegian Cause of Death Registry including 19 289 men ≤80 years diagnosed with non-metastatic prostate cancer during 2010-2019. Patients were treated with radical prostatectomy or definitive radiotherapy. We used competing risk models to compare morbidity from overall CVD, acute myocardial infarction (AMI), cerebral infarction, thromboembolism, and CVD-specific mortality for the overall cohort and stratified by prognostic risk groups.&lt;h4>Results&lt;/h4>Aft</pubmed_abstract><journal>Frontiers in oncology</journal><pagination>1121872</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10102587</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cardiovascular outcomes after curative prostate cancer treatment: A population-based cohort study.</pubmed_title><pmcid>PMC10102587</pmcid><pubmed_authors>Kjellstadli C</pubmed_authors><pubmed_authors>Forster RB</pubmed_authors><pubmed_authors>Myklebust TA</pubmed_authors><pubmed_authors>Bonaa KH</pubmed_authors><pubmed_authors>Kvale R</pubmed_authors><pubmed_authors>Helle SI</pubmed_authors><pubmed_authors>Bjorge T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cardiovascular outcomes after curative prostate cancer treatment: A population-based cohort study.</name><description>&lt;h4>Objective&lt;/h4>To investigate differences in cardiovascular disease (CVD) morbidity and mortality after radical prostatectomy or definitive radiotherapy with or without androgen deprivation therapy (ADT).&lt;h4>Materials and methods&lt;/h4>We used population-based data from the Cancer Registry of Norway, the Norwegian Patient Registry and the Norwegian Cause of Death Registry including 19 289 men ≤80 years diagnosed with non-metastatic prostate cancer during 2010-2019. Patients were treated with radical prostatectomy or definitive radiotherapy. We used competing risk models to compare morbidity from overall CVD, acute myocardial infarction (AMI), cerebral infarction, thromboembolism, and CVD-specific mortality for the overall cohort and stratified by prognostic risk groups.&lt;h4>Results&lt;/h4>Aft</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-04T12:44:01.428Z</modification><creation>2025-04-04T12:44:01.428Z</creation></dates><accession>S-EPMC10102587</accession><cross_references><pubmed>37064117</pubmed><doi>10.3389/fonc.2023.1121872</doi></cross_references></HashMap>